These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

770 related articles for article (PubMed ID: 32332016)

  • 1. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.
    Ricciuti B; Recondo G; Spurr LF; Li YY; Lamberti G; Venkatraman D; Umeton R; Cherniack AD; Nishino M; Sholl LM; Shapiro GI; Awad MM; Cheng ML
    Clin Cancer Res; 2020 Aug; 26(15):4135-4142. PubMed ID: 32332016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual Biomarker Combining DNA Damage Repair Gene Mutations and PD-L1 Expression for Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
    Kim H; Lim DH; Kwon YS; Kim MA; Park KU
    Anticancer Res; 2023 May; 43(5):2343-2349. PubMed ID: 37097676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor mutational burden as a predictive biomarker for non-small cell lung cancer treated with immune checkpoint inhibitors of PD-1/PD-L1.
    Shao MM; Xu YP; Zhang JJ; Mao M; Wang MC
    Clin Transl Oncol; 2024 Jun; 26(6):1446-1458. PubMed ID: 38190035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.
    Yoshida H; Nomizo T; Ozasa H; Tsuji T; Funazo T; Yasuda Y; Ajimizu H; Yamazoe M; Kuninaga K; Ogimoto T; Hosoya K; Itotani R; Sakamori Y; Kim YH; Hirai T
    Eur J Cancer; 2021 Feb; 144():317-325. PubMed ID: 33385948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer.
    Joshi M; Grivas P; Mortazavi A; Monk P; Clinton SK; Sue-Ann Woo M; Holder SL; Drabick JJ; Yin M
    Cancer Med; 2020 Dec; 9(24):9365-9372. PubMed ID: 33098265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of tumor mutation burden and DNA damage repair in advanced stage non-small cell lung cancer patients.
    Zhang H; Deng YM; Chen ZC; Tang YC; Yang S; Zhang SD; Liang JM; Wang YG; Wu X; Zhang RW; Feng WN
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7664-7672. PubMed ID: 32744692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.
    Ricciuti B; Wang X; Alessi JV; Rizvi H; Mahadevan NR; Li YY; Polio A; Lindsay J; Umeton R; Sinha R; Vokes NI; Recondo G; Lamberti G; Lawrence M; Vaz VR; Leonardi GC; Plodkowski AJ; Gupta H; Cherniack AD; Tolstorukov MY; Sharma B; Felt KD; Gainor JF; Ravi A; Getz G; Schalper KA; Henick B; Forde P; Anagnostou V; Jänne PA; Van Allen EM; Nishino M; Sholl LM; Christiani DC; Lin X; Rodig SJ; Hellmann MD; Awad MM
    JAMA Oncol; 2022 Aug; 8(8):1160-1168. PubMed ID: 35708671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
    Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
    Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
    Sabari JK; Leonardi GC; Shu CA; Umeton R; Montecalvo J; Ni A; Chen R; Dienstag J; Mrad C; Bergagnini I; Lai WV; Offin M; Arbour KC; Plodkowski AJ; Halpenny DF; Paik PK; Li BT; Riely GJ; Kris MG; Rudin CM; Sholl LM; Nishino M; Hellmann MD; Rekhtman N; Awad MM; Drilon A
    Ann Oncol; 2018 Oct; 29(10):2085-2091. PubMed ID: 30165371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer.
    Hurkmans DP; Basak EA; Schepers N; Oomen-De Hoop E; Van der Leest CH; El Bouazzaoui S; Bins S; Koolen SLW; Sleijfer S; Van der Veldt AAM; Debets R; Van Schaik RHN; Aerts JGJV; Mathijssen RHJ
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.
    Hastings K; Yu HA; Wei W; Sanchez-Vega F; DeVeaux M; Choi J; Rizvi H; Lisberg A; Truini A; Lydon CA; Liu Z; Henick BS; Wurtz A; Cai G; Plodkowski AJ; Long NM; Halpenny DF; Killam J; Oliva I; Schultz N; Riely GJ; Arcila ME; Ladanyi M; Zelterman D; Herbst RS; Goldberg SB; Awad MM; Garon EB; Gettinger S; Hellmann MD; Politi K
    Ann Oncol; 2019 Aug; 30(8):1311-1320. PubMed ID: 31086949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patients.
    Gu W; Zhuang W; Zhuang M; He M; Li Z
    Diagn Pathol; 2023 Nov; 18(1):119. PubMed ID: 37924135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
    Chen Y; Liu Q; Chen Z; Wang Y; Yang W; Hu Y; Han W; Zeng H; Ma H; Dai J; Zhang H
    J Exp Clin Cancer Res; 2019 May; 38(1):193. PubMed ID: 31088500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.